Table 1 Patients’ characteristics for both training set and validation set
Variables | Training set n = 277 | Validation set n = 119 | P value |
|---|---|---|---|
Age (year, mean ± standard deviation) | 55.0 ± 9.5 | 54.2 ± 9.9 | 0.4622 |
SCC-Ag | Â | Â | 0.708 |
  ≤ 11.5 ng/ml | 200 (72.20%) | 83 (69.75%) |  |
 11.5 ng/ml | 77 (27.80%) | 36 (30.25%) |  |
Tumor volume (cm3) | Â | Â | 0.6936 |
  ≤ 28.85 | 131 (47.29%) | 53 (44.54%) |  |
  > 28.85 | 146 (52.71%) | 66 (55.46%) |  |
Poor differentiation | Â | Â | 0.853 |
 No | 229 (82.67%) | 100 (84.03%) |  |
 Yes | 48 (17.33%) | 19 (15.97%) |  |
Hemoglobin concentration (g/L) | Â | Â | 0.4388 |
  ≥ 120 | 209 (75.45%) | 83 (69.75%) |  |
 90 g/L ~ 119 | 46 (16.61%) | 26 (21.85%) |  |
  < 90 | 22 (7.94%) | 10 (8.40%) |  |
Parametrial invasion | Â | Â | 0.6113 |
 No | 24 (8.66%) | 10 (8.40%) |  |
 Parametrial invasion | 139 (50.18%) | 66 (55.46%) |  |
 Pelvic wall extension | 114 (41.16%) | 43 (36.13%) |  |
FIGO2018 stage | Â | Â | 0.4027 |
 II | 97 (35.02%) | 49 (41.18%) |  |
 IIIa and IIIb | 64 (23.10%) | 19 (15.97%) |  |
 IIIc1r | 99 (35.74%) | 43 (36.13%) |  |
 IIIc2r | 17 (6.14%) | 8 (6.72%) |  |
Chemotherapy | Â | Â | 0.5438 |
 No | 53 (19.13%) | 19 (15.97%) |  |
 Yes | 224 (80.87%) | 100 (84.03%) |  |
Radiotherapy modality | Â | Â | 0.6598 |
 Conventional radiotherapy | 157 (56.68%) | 71 (59.66%) |  |
 IMRT | 120 (43.32%) | 48 (40.34%) |  |
Time of radiotherapy(day) | Â | Â | 0.3521 |
  ≤ 56 | 101 (36.46%) | 50 (42.02%) |  |
  > 56 | 176 (63.54%) | 69 (57.98%) |  |
EQD2 dose of point A (Gy) | Â | Â | 0.8446 |
  ≤ 85 | 45 (16.25%) | 21 (17.65%) |  |
  > 85 | 232 (83.75%) | 98 (82.35%) |  |
Status | Â | Â | 0.6846 |
 Alive/Censored | 224 (80.87%) | 99 (83.19%) |  |
 Dead | 53 (19.13%) | 20 (16.81%) |  |